Helped by growth in the biosimilars and generics segments, biotechnology company Biocon reported topline and bottom-line growth of 21.6% and 72% on a y-o-y basis in the first quarter of 2022-23. However, higher cost pressures impacted the operating profit margins, which contracted 343 basis points y-o-y.

The acquisition of Viatris and vaccine partnership with Serum Institute has helped the company to position itself as an integrated global